Reversal of General Anesthesia With Methylphenidate
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post Operative Cognitive Dysfunction; Emergence From Anesthesia
Intervention: Methylphenidate (Drug)
Phase: Phase 1/Phase 2
Status: Enrolling by invitation
Sponsored by: Massachusetts General Hospital
Summary
The aim of this study is to investigate whether methylphenidate (Ritalin) can actively
induce emergence from general anesthesia in patients having a pancreaticoduodenectomy
(Whipple procedure).
Clinical Details
Official title: Reversal of Propofol-Induced General Anesthesia With Intravenous Methylphenidate
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Primary outcome: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Secondary outcome: Time to emergence from general anesthesia
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 18-75 years
- American Society of Anesthesiologists classification 1 or 2
- Scheduled to undergo a pancreaticoduodenectomy or distal pancreatectomy at
Massachusetts General Hospital
Exclusion Criteria:
- American Society of Anesthesiologists physical status classification of 3 or beyond.
Locations and Contacts
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Starting date: November 2014
Last updated: April 8, 2015
|